Journal of Innate Immunity

Research Article

Free Access

The Effect of HMGB1, a Damage-Associated Molecular Pattern Molecule, on Polymorphonuclear Neutrophil Migration Depends on Its Concentration

Berthelot F. · Fattoum L. · Casulli S. · Gozlan J. · Maréchal V. · Elbim C.

Author affiliations

Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, UMR S 872 et Université Paris Descartes, UMR S 872, INSERM, Paris, France

Corresponding Author

Prof. Carole Elbim

Centre de Recherche des Cordeliers

Université Pierre et Marie Curie – Paris 6, UMR S 872

15 rue de l’École de Médecine, FR–75006 Paris (France)

Tel. +33 1 44 27 71 09, E-Mail carole.elbim@upmc.fr

Keywords: NeutrophilsAlarmineChemotaxisInflammation

Related Articles for ""
J Innate Immun 2012;4:41–58
https://doi.org/10.1159/000328798

Abstract

Polymorphonuclear neutrophils (PMN) play a key role in host defenses against invading microorganisms but also potentiate inflammatory reactions in case of excessive or misdirected responses. Release of the alarmin high-mobility group box 1 (HMGB1) by cells that die at an inflammatory site may act as an alert signal for the immune system. We studied the effect of HMGB1 on human PMN migration, using whole-blood samples to avoid cell activation associated with isolation procedures. HMGB1 50–100 ng/ml reduced baseline PMN migration as well as formyl-methionyl-leucyl-phenylalanine- and IL-8-induced PMN chemotaxis. This inhibitory effect was mediated by the RAGE receptor. In contrast, a higher HMGB1 concentration (5,000 ng/ml) had a chemoattractant effect on PMN through IL-8 production. This effect required the engagement of Toll-like receptors 2 and 4 in addition to the RAGE receptor. The A box component of HMGB1, which antagonizes the endogenous protein, reduced chemotaxis and also strongly inhibited the enhancement of PMN migration observed with the highest HMGB1 concentration. In contrast, the B box, reported to be the active form of HMGB1, exerted a chemoattractant effect. These results strongly point to a key regulatory role of HMGB1 in PMN recruitment to inflammatory tissues. The A box component could potentially serve to inhibit inappropriate PMN recruitment during chronic inflammatory disorders associated with excessive HMGB1 release.

© 2011 S. Karger AG, Basel



Related Articles:

References

  1. Babior BM: Oxidants from phagocytes: agents of defense and destruction. Blood1984;64:959–966.
    External Resources
  2. Bokoch GM: Chemoattractant signaling and leukocyte activation. Blood1995;86:1649–1660.
    External Resources
  3. Bianchi ME, Manfredi AA: High mobility group box 1 (HMGB1) protein at the crossroads between native and adaptive immunity. Immunol Rev 2007;220:35–46.
    External Resources
  4. Sha Y, Zmijewski J, Xu Z, Abraham E: HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 2008;180:2531–2537.
    External Resources
  5. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Peter A, Kiener PA, Coyle AJ: Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8:487–496.
    External Resources
  6. Youn JH, Oh YJ, Kim ES, Choi JE, Shin JS: High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-α production in human monocytes. J Immunol 2008;180:5067–5074.
    External Resources
  7. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, Czura CJ, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U, Tracey KJ: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004;101:296–301.
    External Resources
  8. Orlova VV, Choi EY, Xie C, Chavakis E, Bierhaus A, Ihanus E, Ballantyne CM, Gahmberg CG, Bianchi ME, Nawroth PP, Chavakis T: A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 2007;26:1129–1139.
    External Resources
  9. Kuijpers TW, Tool ATJ, Van der Schoot CE, Ginsel LA, Onderwater JJM, Roos D, Verhoeven AJ: Membrane surface antigen expression on neutrophils: a reappraisal of the use of surface markers for neutrophil activation. Blood 1991;78:1105–1111.
    External Resources
  10. Jaouen S, de Koning L, Gaillard C, Muselikova-Polanska E, Stros M, Strauss F: Determinants of specific binding of HMGB1 protein to hemicatenated DNA loops. J Mol Biol 2005;353:822–837.
    External Resources
  11. Thierry S, Gozlan J, Jaulmes A, Boniface R, Nasreddine N, Strauss F, Maréchal V: High-mobility group box 1 protein induces HIV-1 expression from persistently infected cells. AIDS 2007;21:283–292.
    External Resources
  12. Gaillard C, Borde C, Gozlan J, Maréchal V, Strauss F: A high-sensitivity method for detection and measurement of HMGB1 protein concentration by high-affinity binding to DNA hemicatenanes. PLoS ONE 2008;3:e2855.
    External Resources
  13. Palumbo R, De Marchis F, Pusterla T, Conti A, Alessio M, Bianchi ME: Src family kinases are necessary for cell migration induced by extracellular HMGB1. J Leukoc Biol 2009;86:617–623.
    External Resources
  14. Elbim C, Monceaux V, Mueller YM, Lewis MG, François S, Diop O, Akarid K, Hurtrel B, Gougerot-Pocidalo MA, Levy Y, Katsikis PD, Estaquier J: Early divergence in neutrophil apoptosis between pathogenic and non-pathogenic SIV infections of non-human primates. J Immunol 2008;181:8613–8623.
    External Resources
  15. François S, El Benna J, Dang PMC, Pedruzzi E, Gougerot-Pocidalo MA, Elbim C: Inhibition of neutrophil apoptosis by Toll-like receptor agonists in whole blood: involvement of the phosphoinositide 3-kinase/Akt and NF-ĸB signaling pathways leading to increased levels of Mcl-1, A1 and phosphorylated Bad. J Immunol 2005;174:3633–3642.
    External Resources
  16. Elbim C, Chollet-Martin S, Bailly S, Hakim J, Gougerot-Pocidalo MA: Priming of polymorphonuclear neutrophils (PMN) by tumor necrosis factor α in whole blood: identification of two PMN subpopulations in response to formyl-peptides. Blood 1993;82:633–640.
    External Resources
  17. Wlodkowic D, Skommer J, Pelkonen J: Towards an understanding of apoptosis detection by SYTO dyes. Cytometry A 2007;71A: 61–72.
    External Resources
  18. Wymann MP, Kernen P, Bengtsson T, Andersson T, Baggiolini M, Deranleau DA: Corresponding oscillations in neutrophil shape and filamentous actin content. J Biol Chem 1990;265:619–622.
    External Resources
  19. Powner DJ, Pettitt TR, Anderson R, Nash GB, Wakelam MJ: Stable adhesion and migration of human neutrophils requires phospholipase D-mediated activation of the integrin CD11b/CD18. Mol Immunol 2007;44:3211–3221.
    External Resources
  20. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, Ishizaka A, Abraham E: High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006;290:C917–C924.
    External Resources
  21. Weiss SJ: Tissue destruction by neutrophils. N Engl J Med 1989;320:365–376.
    External Resources
  22. Touré F, Zahm JM, Garnotel R, Lambert E, Bonnet N, Schmidt AM, Vitry F, Chanard J, Gillery P, Rieu P: Receptor for advanced glycation end-products (RAGE) modulates neutrophil adhesion and migration on glycoxidated extracellular matrix. Biochem J 2008;416:255–261.
    External Resources
  23. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, Dumitriu IE, Müller S, Iannacone M, Traversari C, Bianchi ME, Manfredi AA: HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004;5:825–830.
    External Resources
  24. Takata S, Matsubara M, Allen PG, Janmey PA, Serhan CN, Brady HR: Remodeling of neutrophil phospholipids with 15(S)-hydroxyeicosatetraenoic acid inhibits leukotriene B4-induced neutrophil migration across endothelium. J Clin Invest 1994;93:499–508.
    External Resources
  25. Ly NP, Komatsuzaki K, Fraser IP, Tseng AA, Prodhan P, Moore KJ, Kinane TB: Netrin-1 inhibits leukocyte migration in vitro and in vivo. Proc Natl Acad Sci USA 2005;102:14729–14734.
    External Resources
  26. Hayhoe RP, Kamal AM, Solito E, Flower RJ, Cooper D, Perretti M: Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. Blood 2006;107:2123–2130.
    External Resources
  27. Bournazou I, Pound JD, Duffin R, Bournazos S, Melville LA, Brown SB, Rossi AG, Gregory CD: Apoptotic human cells inhibit migration of granulocytes via release of lactoferrin. J Clin Invest 2009;119:20–32.
    External Resources
  28. Kokkola R, Li J, Sundberg E, Aveberger AC, Pamblad K, Yang H, Tracey KJ, Andersson U, Harris HE: Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003;48:2052–2058.
    External Resources
  29. Rowe SM, Jackson PL, Liu G, Hardison M, Livraghi A, Solomon GM, McQuaid DB, Noerager BD, Gaggar A, Clancy JP, O’Neal W, Sorscher EJ, Abraham E, Blalock JE: Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 2008;178:822–831.
    External Resources
  30. Elbim C, Bailly S, Chollet-Martin S, Hakim J, Gougerot-Pocidalo MA: Differential priming effects of proinflammatory cytokines on human neutrophil oxidative burst in response to bacterial N-formyl peptides.Infection and Immunity 1994;62:2195–2201.
    External Resources
  31. Fan J, Malik AB: Toll-like receptor-4 (TLR4) signaling augments chemokine-induced neutrophil migration by modulating cell surface expression of chemokine receptors. Nat Med 2003;9:315–321.
    External Resources
  32. Knall C, Worthen GS, Johnson GL: Interleukin 8-stimulated phosphatidylinositol-3- kinase activity regulates the migration of human neutrophils independent of extracellular signal-regulated kinase and p38 mitogen-activated protein kinases. Proc Natl Acad Sci USA 1997;94:3052–3057.
    External Resources
  33. Oppermann M, Mack M, Proudfoot AEI, Olbrich H: Differential effects of CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxy terminus. J Biol Chem 1999;274:8875–8885.
    External Resources
  34. Peregrin S, Jurado-Pueyo M, Campos PM, Sanz-Moreno V, Ruiz-Gomez A, Crespo P, Mayor F, Murga C: Phosphorylation of p38 by GRK2 at the docking groove unveils a novel mechanism for inactivating p38MAPK. Curr Biol 2006;16:2042–2047.
    External Resources
  35. Tatsukawa T, Chimura T, Miyakawa H, Yamaguchi K: Involvement of basal protein kinase C and extracellular signal-regulated kinase 1/2 activities in constitutive internalization of AMPA receptors in cerebral Purkinje cells. J Neurosci 2006;26:4820–4825.
    External Resources
  36. Wolff M, Kredel WM, Haasen D, Wiedenmann J, Nienhaus GU, Kistler B, Oswald F, Heilker R: High content screening of CXCR2-dependent signalling pathways. Comb Chem High Throughput Screen 2010;13:3–15.
    External Resources
  37. Chen GY, Tang J, Zheng P, Liu Y: CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009;323:1722–1725.
    External Resources
  38. Landsman D, Bustin MA: Signature for the HMG-1 box DNA-binding proteins. Bioassays 1993;15:539–546.
    External Resources
  39. Yuan H, Jin X, Sun J, Li F, Feng Q, Zhang C, Cao Y, Wang Y: Protective effect of HMGB1 A box on organ injury of acute pancreatitis in mice. Pancreas 2009;38:143–148.
    External Resources
  40. Muhammad S, Barakat W, Stroyanov S, Murikinati S, Yang H, Tracey KJ, Bendszus M, Rossetti G, Nawroth PP, Bierhaus A, Schwaninger M: The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 2008;28:12023–12120.
    External Resources
  41. Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya S, Buss S, Autschbach F, Pleger ST, Lukic IK, Bea F, Hardt SE, Humpert PM, Bianchi ME, Mairbäurl H, Nawroth PP, Remppis A, Katus HA, Bierhaus A: High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008;117:3216–3226.
    External Resources
  42. Huang Y, Yin H, Han J, Huang B, Xu J, Zheng F, Tan Z, Fang M, Rui L, Chen D, Wang S, Zheng X, Wang CY, Gong F: Extracellular HMGB1 functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection. Am J Transplant 2007;4:799–808.
    External Resources
  43. Gong Q, Xu JF, Yin H, Liu SF, Duan LH, Bian ZL: Protective effect of antagonist of high-mobility group box 1 on lipopolysaccharide-induced acute lung injury in mice. Scand J Immunol 2009;69:29–35.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Research Article

Received: November 04, 2010
Accepted: April 18, 2011
Published online: August 19, 2011
Issue release date: December 2011

Number of Print Pages: 18
Number of Figures: 7
Number of Tables: 0

ISSN: 1662-811X (Print)
eISSN: 1662-8128 (Online)

For additional information: https://www.karger.com/JIN

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2012, Vol.4, No. 1

December 2011

Free Supplementary Material

Article

Recommend This
Open Access Gateway
TOP